The co-encapsulation StII with a model antigen into liposomes has been shown to induce an antigen-specific CD8+ T cell response and potent anti-tumor immunity resulting in a promising vaccine platform for cancer immunotherapy (16). The gene discussed is CD8A; the disease is cancer.